Imricor Medical Systems has broadened its interventional magnetic resonance imaging (iMRI) portfolio with the introduction of Imricor Cardiovascular, a dedicated business focused on advancing radiation-free cardiac catheterization. The launch marks an important expansion beyond the company’s established electrophysiology and ablation business and follows recent U.S. Food and Drug Administration clearances for its NorthStar system and Vision-MR Diagnostic Catheter.
The new division is intended to help hospitals establish interventional MRI programs capable of performing cardiac catheterization procedures using magnetic resonance imaging instead of conventional X-ray guidance. By combining advanced visualization with interventional procedures in a single environment, Imricor is positioning its technology as an alternative workflow for healthcare providers seeking to improve procedural efficiency while reducing radiation exposure.
The launch also reflects broader advances in cardiac ablation technologies, where hospitals are increasingly investing in image-guided platforms that improve procedural precision while minimizing patient exposure to radiation. As interventional cardiology continues to adopt advanced imaging solutions, MRI-guided procedures are emerging as a complementary approach capable of supporting both diagnostic and therapeutic cardiac interventions.
MRI-guided cardiac catheterization aims to improve workflow and patient care
Imricor Cardiovascular has been developed around the concept of performing cardiac catheterization procedures inside an interventional MRI laboratory rather than relying on traditional catheterization suites equipped with fluoroscopy.
Conventional cardiac procedures frequently require patients to undergo separate magnetic resonance imaging before or after catheterization, often resulting in multiple appointments, repeated patient transfers, and longer overall treatment pathways. Imricor’s integrated approach seeks to consolidate imaging and intervention into a single clinical session.
According to the company, this workflow may reduce overall procedural time while enabling hospitals to make more efficient use of existing catheterization laboratory resources. Performing imaging and intervention simultaneously can also free conventional X-ray catheterization suites for other cardiovascular procedures, potentially improving hospital capacity and scheduling flexibility.
For healthcare organizations facing increasing procedural volumes, optimizing workflow has become an important operational objective. Hospitals continue to balance growing demand for cardiovascular services with workforce shortages, equipment utilization, and rising operational costs. Technologies capable of reducing procedure duration while maintaining clinical quality are therefore attracting greater attention across the cardiovascular sector.
The company estimates that the integrated workflow may contribute to procedural time savings of approximately 35 percent compared with conventional approaches involving separate imaging and catheterization sessions.
MRI guidance also provides physicians with detailed anatomical, functional, and tissue characterization throughout the intervention. Unlike fluoroscopic imaging, magnetic resonance imaging offers superior soft tissue visualization without exposing patients or clinical staff to ionizing radiation.
The introduction of Imricor Cardiovascular builds upon recent regulatory milestones for the company’s imaging platform, strengthening its commercial portfolio within the rapidly evolving field of MRI-guided cardiovascular intervention.
Pediatric and congenital heart care emerge as key opportunities
While the technology has broad cardiovascular applications, Imricor expects one of its most significant clinical opportunities to emerge within pediatric cardiology and congenital heart disease.
Children born with complex heart defects frequently undergo numerous catheterization procedures throughout childhood and adolescence. Repeated exposure to ionizing radiation has long been recognized as a concern for these patients because cumulative radiation doses increase over multiple interventions performed over many years.
MRI-guided catheterization offers the possibility of performing these procedures without radiation exposure while simultaneously providing physicians with detailed functional and anatomical information that can support clinical decision-making.
Another potential advantage lies in reducing the number of separate hospital visits. Instead of scheduling magnetic resonance imaging and catheterization independently, patients may undergo both components during a single procedure. Fewer clinical sessions may reduce anesthesia exposure while simplifying treatment planning for patients, caregivers, and healthcare teams.
The streamlined approach may also improve hospital resource utilization by minimizing repeated scheduling, patient transfers, and duplicate preparation processes.
Imricor executives describe the launch as an important step toward establishing a new model for cardiovascular intervention built around advanced imaging rather than conventional fluoroscopy.
For hospitals, adopting interventional MRI technology could create opportunities to differentiate specialized cardiovascular programs while expanding advanced imaging capabilities. Institutions investing early in MRI-guided catheterization may position themselves among a relatively small number of centers currently offering radiation-free interventional cardiac procedures in the United States.
The company’s broader strategy also reflects increasing momentum within image-guided cardiovascular medicine. Advances in imaging technology, catheter design, software integration, and procedural planning continue reshaping how complex cardiac interventions are performed across electrophysiology, structural heart disease, and congenital cardiology.
Imricor’s existing expertise in MRI-compatible electrophysiology systems provides an established foundation for this expansion. Extending into diagnostic and interventional cardiovascular procedures allows the company to address a broader segment of the cardiovascular imaging market while leveraging its existing technology platform.
Healthcare providers are also placing greater emphasis on improving patient experience alongside procedural outcomes. Reducing radiation exposure, minimizing hospital visits, shortening treatment timelines, and simplifying clinical workflows align with broader trends toward patient-centered care delivery.
As hospitals evaluate future investments in cardiovascular infrastructure, integrated imaging platforms capable of supporting multiple interventional applications are expected to become increasingly attractive. The ability to combine advanced visualization with real-time procedural guidance may improve both operational efficiency and clinical decision-making across selected patient populations.
With the launch of Imricor Cardiovascular, the company is expanding beyond its traditional electrophysiology business to establish a broader presence within MRI-guided cardiovascular intervention. By promoting radiation-free catheterization supported by high-resolution magnetic resonance imaging, Imricor aims to support hospitals seeking new approaches to cardiovascular care while creating additional opportunities for innovation in pediatric, congenital, and structural heart procedures. The initiative reflects the growing role of advanced imaging technologies in shaping the future of minimally invasive cardiovascular treatment.
